about
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cellsLipid free apolipoprotein E binds to the class B Type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteinsSox17 regulates liver lipid metabolism and adaptation to fastingBone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis developmentPeroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in miceRexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly.Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.Apolipoprotein A-II, HDL metabolism and atherosclerosis.The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinomaMurine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation.Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice.p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages.Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.Roles of PPARs in NAFLD: potential therapeutic targets.Bariatric surgery, lipoprotein metabolism and cardiovascular risk.Tau deletion promotes brain insulin resistanceMetabolic effects of bile acid sequestration: impact on cardiovascular risk factors.Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1.Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction.Cdkn2a/p16Ink4a regulates fasting-induced hepatic gluconeogenesis through the PKA-CREB-PGC1α pathway.Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits.Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine.Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta.HDL heterogeneity and atherosclerosis.Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways.Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation.Morphologic and electroretinographic phenotype of SR-BI knockout mice after a long-term atherogenic diet.Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects.Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention.Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans.PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.
P50
Q27324038-BD903928-82B5-44C2-8528-9B450158C4B5Q28215780-547286B3-3473-4A7B-A829-0F5CD9DE392AQ28542411-A5B2CA28-FCE3-419D-963D-11248855D608Q28731544-3417D1B8-6DCF-410B-B38F-A69B443184AEQ30513404-5635EE63-3A36-4C49-B82E-641ED524C858Q33670343-FDDC2C51-9F55-4294-AE40-77C8048EA7C7Q34036872-E84218FB-521A-4334-B7D3-A40B0AB2E522Q34382248-DA9D8843-BC56-4939-B14D-5506C68F3FBEQ34479025-49DD61FA-E4F1-4C93-A3DC-3FF22C97F08AQ34740994-D25EA339-6D2F-416B-B50C-9F9D0B66FEB9Q34857971-1BA35DD8-36C0-4E40-9365-21F0873B123EQ35134601-1CC1FC16-6037-48F0-A450-C35F8404213AQ35559762-66BC3239-A098-4880-B7FC-714C8CBABD33Q36754820-EB78E406-0FD6-4FD7-B96F-23D4A981A547Q36796015-09CF15F2-56F5-404C-966A-CFA321CAF787Q36916423-C5348C44-C5CE-4854-891C-2A8BF4733933Q37295504-D07F75BD-5986-4B17-BFAC-9A2DB8510858Q37699483-A80F224B-26B8-4C11-95A8-9E65658DB07CQ37953148-6A4BC9FE-5595-4305-BD88-A6F623A27042Q38535563-A97FBCD8-28FE-4C77-88EF-11F10C85D5B0Q38708062-6F5D0502-7D42-48A1-B172-D29A6983D4E0Q38727310-77F659C9-2BC2-476D-B94B-37C0F45C3AE1Q38817108-82A12FD4-C586-4A21-8973-776A0D559022Q38854649-2C06320E-2DD8-433A-B5C2-28C972529B30Q38999261-A426566B-FCC1-460C-B06C-FF313E26D40CQ39142100-7311D821-2962-4BAE-848A-B4A785D1C562Q39365925-170C2200-F089-4263-B2FB-31EA43B6AE3DQ40329287-4C9C28D4-87DC-4740-AE3F-25127F58EB77Q40727096-0C2FB98B-0717-4E2D-B7FF-F24F5EA3B323Q41128681-113152F1-E59B-44D9-BB12-7A555E3D482BQ42557215-39158C7E-3E16-416C-88FE-D6FAF04AA707Q44086411-60639FBA-9761-448B-9F1B-7C446589597EQ46023211-4DDDE714-7CCE-4364-A3AD-7FA9FF5AD480Q46212721-90CD6029-C20F-46D3-BD8D-34F754006F45Q46302614-C66780A7-5479-4A04-866F-6ACC78B3349DQ46424141-523F41F4-F98E-41B8-9E23-3F4373F24855Q46427939-C3B81DCC-8BE1-431C-A6EC-3CC70C706F4CQ46561979-E83426C6-0CBB-4FFB-9767-F43E7D133F04Q46580812-ABD56DC6-1939-4690-A8F9-120EB70DB019Q46664242-94DB3C4E-17DD-40A3-ADAB-D815136DC32A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anne Tailleux
@ast
Anne Tailleux
@en
Anne Tailleux
@es
Anne Tailleux
@nl
type
label
Anne Tailleux
@ast
Anne Tailleux
@en
Anne Tailleux
@es
Anne Tailleux
@nl
altLabel
Anne TAILLEUX
@en
prefLabel
Anne Tailleux
@ast
Anne Tailleux
@en
Anne Tailleux
@es
Anne Tailleux
@nl
P1053
R-5530-2018
P106
P21
P31
P496
0000-0003-1430-2627